Repare Therapeutics 株価情報 (NASDAQ: RPTX)

最新ニュース Repare Therapeutics (NASDAQ:RPTX) 株価情報

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Repare Therapeutics Inc

Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key details from the <a href="https://www.benzinga.com/pressreleases/25/05/b45269632/cleveland-cliffs-reports-first-quarter-2025-results">steel producer&#8217;s report</a>.
Q1 Earnings: Cleveland-Cliffs reported first-quarter revenue of $4.63 billion, missing analyst <a href="http://benzinga.com/quote/clf/earnings">estimates</a> of $4.64 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The steelmaker reported a first-quarter adjusted loss of 92 cents per share, missing analyst estimates for a loss of 75 cents per share. 
Between March and May, the company decided to fully or partially idle six facilities to optimize its footprint, reposition away from loss-making operations and release excess working capital. These actions are expected to result in savings of over $300 million annually. 
&#8220;The decision to fully or partially idle certain locations was not taken lightly,&#8221; the company said. 
Total steelmaking revenues&nbsp;included&nbsp;$1.4 billion to the infrastructure and manufacturing market, $1.3 billion to the automotive market, $1.2 billion to the distributors and converters market and&nbsp;$588 million to steel producers.
Steel product sales volumes totaled 4.1 million net tons&nbsp;in the first quarter, consisting of 41%&nbsp;hot-rolled,&nbsp;27%&nbsp;coated,&nbsp;15%&nbsp;cold-rolled,&nbsp;5%&nbsp;plate,&nbsp;3%&nbsp;stainless and electrical and&nbsp;9%&nbsp;other.
Cleveland-Cliffs ended the quarter with $3 billion in total liquidity. 
&#8220;Our&nbsp;first-quarter&nbsp;results were negatively impacted by underperforming non-core assets and the lagging effect of lower index prices in late 2024 and early 2025,&#8221; said Lourenco Goncalves, chairman, president and CEO of Cleveland-Cliffs.
&#8220;As a result, we are taking decisive action to streamline our operations and enhance efficiency. This will drive meaningful fixed cost savings and sharpen our focus on our core strength: supplying steel to the automotive industry.&#8221;
Outlook: Cleveland-Cliffs expects full-year 2025 steel unit cost reductions of approximately&nbsp;$50&nbsp;per net ton compared to the prior year. The company anticipates full-year capital expenditures of approximately $625 million, down from prior guidance of $700 million. 
Cleveland-Cliffs executives will hold a conference call at 8:30 a.m. Thursday morning to further discuss the quarter with investors and analysts. 
CLF Price Action: <a href="http://benzinga.com/quote/clf">Cleveland-Cliffs shares</a> were down 9.19% after-hours, trading at $7.71 at the time of publication Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268560/carvana-q1-earnings-revenue-eps-beat-estimates-as-vehicles-sales-jump-46-company-remains-on-track-for-significant-growth-in-fy25">Carvana Q1 Earnings: Revenue, EPS Beat Estimates As Vehicles Sales Jump 46%, Company Remains On Track For &#8216;Significant Growth&#8217; In FY25</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268429/arm-holdings-stock-plunges-after-q4-results-heres-why">Arm Holdings Stock Plunges After Q4 Results: Here&#8217;s Why</a></li>
</ul>
Photo: saweang.w/Shutterstock.

Earnings

News

Guidance

Commodities

After-Hours Center

Movers

Cleveland-Cliffs Stock Falls On Q1 Earnings Miss, Steelmaker Idles 6 Facilities: 'Taking Decisive Action To Streamline Our Operations'

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

SDGR

Schrodinger Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.68% on an annualized basis producing an average annual return of 16.77%. Currently, Verisk Analytics has a market capitalization of $43.47 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,035.76 today based on a price of $309.90 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746654312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VRSK

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) affirms FY2025 sales outlook from $50.00 million-$53.00 million to $50.00 million-$53.00 million vs $61.78 million estimate.

Myomo Affirms FY2025 Sales Guidance of $50.00M-$53.00M vs $61.78M Est

Energy Fuels (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 750 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $16.90 million which beat the analyst consensus estimate of $15.20 million by 11.17 percent. This is a 33.54 percent decrease over sales of $25.43 million the same period last year.

Earnings Beats

Earnings Misses

UUUU

Energy Fuels Q1 EPS $(0.13) Misses $(0.05) Estimate, Sales $16.90M Beat $15.20M Estimate

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) sees Q2 sales of $9.000 million-$9.500 million vs $13.60 million analyst estimate.

Myomo Sees Q2 Sales $9.000M-$9.500M vs $13.60M Est

The board of directors of The Brink's Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCO#NYSE">BCO</a>) today declared a regular quarterly dividend of $0.255 cents per share on the company's common stock, an increase of 5%. The dividend is payable on June 2, 2025, to shareholders of record on May 19, 2025.&nbsp;&nbsp;

Dividends

Brink's Increases Quarterly Dividend From $0.24 To $0.255 Per Share

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.75) by 14.67 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $59.55 million which beat the analyst consensus estimate of $54.65 million by 8.96 percent. This is a 62.72 percent increase over sales of $36.60 million the same period last year.

Schrodinger Q1 Adj. EPS $(0.64) Beats $(0.75) Estimate, Sales $59.55M Beat $54.65M Estimate

Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) affirms FY2025 sales outlook from $345.00 million-$355.00 million to $345.00 million-$355.00 million vs $350.97 million estimate.

EOLS

Evolus Affirms FY2025 Sales Guidance of $345.00M-$355.00M vs $350.97M Est

Copa Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>) reported quarterly earnings of $4.28 per share which beat the analyst consensus estimate of $3.77 by 13.53 percent. This is a 2.15 percent increase over earnings of $4.19 per share from the same period last year. The company reported quarterly sales of $899.18 million which beat the analyst consensus estimate of $888.29 million by 1.23 percent. This is a 0.64 percent increase over sales of $893.47 million the same period last year.

Copa Holdings Q1 EPS $4.28 Beats $3.77 Estimate, Sales $899.18M Beat $888.29M Estimate

Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.30 by 63.33 percent. This is a 76.09 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $5.10 billion which missed the analyst consensus estimate of $5.15 billion by 0.97 percent. This is a 5.36 percent decrease over sales of $5.39 billion the same period last year.

Nutrien Q1 EPS $0.11 Misses $0.30 Estimate, Sales $5.10B Miss $5.15B Estimate

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 50 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $59.13 million which missed the analyst consensus estimate of $60.60 million by 2.43 percent. This is a 16.87 percent increase over sales of $50.59 million the same period last year.

Viemed Healthcare Q1 EPS $0.06, Inline, Sales $59.13M Miss $60.60M Estimate

Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) sees Q2 sales of $121.000 million-$123.000 million vs $119.66 million analyst estimate.

GRPN

Groupon Sees Q2 Sales $121.000M-$123.000M vs $119.66M Est

Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) affirms FY2025 sales outlook from $493.00 million-$500.00 million to $493.00 million-$500.00 million vs $496.96 million estimate.

Groupon Affirms FY2025 Sales Guidance of $493.00M-$500.00M vs $496.96M Est

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.14 by 7.14 percent. This is a 31.58 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $247.10 million which beat the analyst consensus estimate of $246.95 million by 0.06 percent. This is a 7.72 percent decrease over sales of $267.77 million the same period last year.

BMBL

Bumble Q1 EPS $0.13 Misses $0.14 Estimate, Sales $247.10M Beat $246.95M Estimate

5N Plus (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VNP#TSX">VNP</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 266.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $88.89 million which beat the analyst consensus estimate of $73.32 million by 21.23 percent. This is a 36.71 percent increase over sales of $65.02 million the same period last year.

TSX:VNP

5N Plus Q1 EPS $0.11 Beats $0.06 Estimate, Sales $88.89M Beat $73.32M Estimate

Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) reported quarterly losses of $(1.37) per share which met the analyst consensus estimate. This is a 29.38 percent increase over losses of $(1.94) per share from the same period last year. The company reported quarterly sales of $784.80 million which missed the analyst consensus estimate of $912.50 million by 13.99 percent. This is a 13.19 percent decrease over sales of $904.00 million the same period last year.

Trinseo Q1 Adj. EPS $(1.37), Inline, Sales $784.80M Miss $912.50M Estimate

GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.46 by 45.65 percent. This is a 54.55 percent decrease over earnings of $0.55 per share from the same period last year. The company reported $137.30 million in sales this quarter. This is a 17.98 percent decrease over sales of $167.40 million the same period last year.

GPRK

GeoPark Q1 EPS $0.25 Misses $0.46 Estimate, Sales $137.30M Down From $167.40M YoY

Plaza Retail REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PLZ#TSX">PLZ</a>) reported quarterly earnings of $0.09 per share. This is a 1.12 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $31.14 million in sales this quarter. This is a 5.30 percent increase over sales of $29.57 million the same period last year.

TSX:PLZ

Plaza Retail REIT Q1 FFO $0.09 Down From $0.09 YoY, Sales $31.14M Up From $29.57M YoY

Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. The company reported quarterly sales of $154.14 million which missed the analyst consensus estimate of $160.75 million by 4.11 percent.

ARMN

Aris Mining Q1 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $154.14M Miss $160.75M Estimate

Press Releases

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Comments

Repare Therapeutics

ニュース

最新ニュース Repare Therapeutics (NASDAQ:RPTX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル